Pfizer Japan Inc. and Eisai Co., Ltd. have introduced a collaboration to co-promote the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec® OD Tablet 75mg in Japan, starting September 1, 2026. The remedy, identified generically as rimegepant sulfate hydrate, is designed for each acute therapy and prophylaxis of migraine.
The partnership goals to reinforce the dissemination of knowledge concerning the suitable use of Nurtec in treating migraine, a neurological dysfunction affecting roughly 8.4% of Japan’s grownup inhabitants. Pfizer will handle the event, manufacturing, distribution, and commercialization of Nurtec, whereas each corporations will present utilization data to medical establishments.
Migraine is a prevalent situation characterised by moderate-to-severe complications and signs corresponding to nausea, vomiting, and sensitivity to gentle and sound. The dysfunction considerably impacts each day life, with girls aged 20-40 being essentially the most affected demographic in Japan.
Through this collaboration, Pfizer and Eisai intend to leverage their experience and healthcare networks to advertise the suitable use of Nurtec, aiming to enhance the standard of life for sufferers affected by migraines. The initiative underscores the businesses’ dedication to addressing unmet medical wants and enhancing affected person care within the neurology sector.